A Randomized, Double-blind, Placebo-controlled, Phase Ⅱ Optimal Dose-finding Study to Determine the Safety and Efficacy of DWP450 in Subjects With Benign Masseteric Hypertrophy
Latest Information Update: 03 Dec 2019
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Hypertrophy
- Focus Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 19 Dec 2017 New trial record